Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Lee

Showing results (131-140 of 145) with videos related to

Pageof 15
Sort By:
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Thyroid : Official Journal of the American Thyroid Association|December 18, 2014
Database and registry research in thyroid cancer: striving for a new and improved national thyroid cancer databaseSaral Mehra, R Michael Tuttle, Mira Milas, et al.
Pest Management Science|March 15, 2025
Aminoisothiazolamides, a new class of potent inhibitors of lysyl-tRNA synthetaseDavid Bernier, David M Barber, Guido Bojack, et al.
Transplantation and Cellular Therapy|April 21, 2021
Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell TransplantationCharlotte McIlwaine Story, Tao Wang, Vijaya Raj Bhatt, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal of Medicinal Chemistry|September 19, 2019
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of EpilepsyThilo Focken, Kristen Burford, Michael E Grimwood, et al.
Genome Biology|June 16, 2007
LongSAGE profiling of nine human embryonic stem cell linesMartin Hirst, Allen Delaney, Sean A Rogers, et al.
British Journal of Pharmacology|June 26, 2024
The contribution of Na<sub>V</sub>1.6 to the efficacy of voltage-gated sodium channel inhibitors in wild type and Na<sub>V</sub>1.6 gain-of-function (GOF) mouse seizure controlJames P Johnson, Thilo Focken, Parisa Karimi Tari, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
Pageof 15

Showing results (131-140 of 145) with videos related to

Sort By:
Pageof 15
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Thyroid : Official Journal of the American Thyroid Association|December 18, 2014
Database and registry research in thyroid cancer: striving for a new and improved national thyroid cancer databaseSaral Mehra, R Michael Tuttle, Mira Milas, et al.
Pest Management Science|March 15, 2025
Aminoisothiazolamides, a new class of potent inhibitors of lysyl-tRNA synthetaseDavid Bernier, David M Barber, Guido Bojack, et al.
Transplantation and Cellular Therapy|April 21, 2021
Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell TransplantationCharlotte McIlwaine Story, Tao Wang, Vijaya Raj Bhatt, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal of Medicinal Chemistry|September 19, 2019
Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na<sub>V</sub>1.6 Inhibitors with Efficacy in Mouse Models of EpilepsyThilo Focken, Kristen Burford, Michael E Grimwood, et al.
Genome Biology|June 16, 2007
LongSAGE profiling of nine human embryonic stem cell linesMartin Hirst, Allen Delaney, Sean A Rogers, et al.
British Journal of Pharmacology|June 26, 2024
The contribution of Na<sub>V</sub>1.6 to the efficacy of voltage-gated sodium channel inhibitors in wild type and Na<sub>V</sub>1.6 gain-of-function (GOF) mouse seizure controlJames P Johnson, Thilo Focken, Parisa Karimi Tari, et al.
Elife|March 2, 2022
NBI-921352, a first-in-class, Na<sub>V</sub>1.6 selective, sodium channel inhibitor that prevents seizures in <i>Scn8a</i> gain-of-function mice, and wild-type mice and ratsJ P Johnson, Thilo Focken, Kuldip Khakh, et al.
Pageof 15